(Q40939096)

25 September 2017

1 reference

title

Hemophilia 1996. New approach to an old disease (English)

1 reference

25 September 2017

0 references

DiMichele D

1

1 reference

25 September 2017

publication date

1 June 1996

1 reference

Pediatric Clinics of North America

25 September 2017

published in

1 reference

25 September 2017

volume

43

1 reference

25 September 2017

issue

3

1 reference

25 September 2017

page(s)

709-736

1 reference

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Christmas disease: a condition previously mistaken for haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

The use of continuous infusion of factor concentrates in the treatment of hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Direct carrier testing in 14 families with haemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hepatocellular carcinoma in hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Characterization of the human factor VIII gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Coagulation factor IX: successful surgical experience with a purified factor IX concentrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Induction of immune tolerance in patients with hemophilia A and inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

The rate of spontaneous mutation of a human gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Comparison of continuous and intermittent Factor VIII concentrate therapy in hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Percutaneous umbilical blood sampling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

The history of haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

THE FORTUNES OF HAEMOPHILIACS IN THE NINETEENTH CENTURY

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

The Significance of Blood Transfusion in Non-A, Non-B Chronic Liver Disease in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Life expectancy of Swedish haemophiliacs, 1831-1980.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Liver transplantation in a hemophiliac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Carrier detection in the hemophilias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Gene therapy and the hemophilias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hepatitis C antibody and chronic liver disease in haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Report of the committee on the genetic constitution of the X chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Plasma assay of fetal factors VIIIC and IX for prenatal diagnosis of haemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Equine haemophilia: report of a case and its response to multiple infusions of heterospecific AHG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Diagnosis of the carrier state in hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hemophilia in the Talmud and Rabbinic Writings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hepatitis, epidemiology and liver function in hemophiliacs in Sweden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Transmission of hepatitis C with pasteurised factor VIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Hyponatremia and seizures in young children given DDAVP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

On the distributions of frequencies of mutation to genes determining harmful traits in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Acquired circulating anticoagulants in hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Alpha interferon for hepatitis C virus infection in haemophilic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Factor IX concentrates for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Molecular cloning of a cDNA encoding human antihaemophilic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Continuous infusion of monoclonal antibody-purified factor VIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Arthroscopic synovectomy for chronic hemophilic synovitis of the knee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Expression of active human factor VIII from recombinant DNA clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Expression of human factor IX in mice after injection of genetically modified myoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor 8().

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

Experiences with recombinant factor VIIa in haemophiliacs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970429-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0031-3955(05)70429-6

1 reference

25 September 2017

1 reference